Short Interest in Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Increases By 33.3%

Emmaus Life Sciences, Inc. (OTCMKTS:EMMAGet Free Report) saw a significant increase in short interest in March. As of March 15th, there was short interest totalling 7,600 shares, an increase of 33.3% from the February 29th total of 5,700 shares. Based on an average daily trading volume, of 20,700 shares, the short-interest ratio is currently 0.4 days.

Emmaus Life Sciences Price Performance

Emmaus Life Sciences stock opened at $0.11 on Monday. The stock’s fifty day moving average is $0.11 and its two-hundred day moving average is $0.11. The stock has a market cap of $6.49 million, a PE ratio of -1.05 and a beta of 1.62. Emmaus Life Sciences has a 1-year low of $0.05 and a 1-year high of $0.35.

About Emmaus Life Sciences

(Get Free Report)

Emmaus Life Sciences, Inc, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Featured Articles

Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.